ImmuPharma plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2023: USD 1.48 M

ImmuPharma plc Selling, General, and Administrative Expenses (SG&A) is USD 1.48 M for the year ending December 31, 2023, a 44.38% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.
  • ImmuPharma plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2022 was USD 1.02 M, a -50.06% change year over year.
  • ImmuPharma plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2021 was USD 2.05 M, a -15.00% change year over year.
  • ImmuPharma plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2020 was USD 2.41 M, a -0.65% change year over year.
  • ImmuPharma plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2019 was USD 2.43 M, a 14.73% change year over year.
Key Data
Date Selling, General, and Administrative Expenses (SG&A) Research and Development (R&D) Expenses Revenue Revenue